PROC - Rasio utang marang kapitalisasi buku Procaps Group

Logo grafis Procaps Group (PROC)

Macroeconomic volatility in Latin America and currency swings are putting pressure on the business of Procaps Group S.A. (PROC). The current debt-to-equity ratio demonstrates financial stability, where the level of 0.00 represents the current value. This correlates with expansion in the US and plant optimization, as well as the company's status as a reliable global partner for softgel capsule production with strict quality control.

PROC (Procaps Group Corp) riwayat Utang marang nilai buku saka 04.07.2022 nganti 16.02.2025
Barang utama Procaps Group SA

Investors use this ratio to assess financial stability and the extent of the business's dependence on external borrowings. The metric is calculated as the ratio of total debt to the sum of equity and liabilities. The trend of the financial debt-to-balance sheet capital ratio on GURU.Markets visualizes the credit load risk. For Procaps Group S.A. (PROC), this is critical when implementing its global expansion strategy. Monitoring this parameter allows for an assessment of the efficiency of capital management by the Miski family.

Pesaing Procaps Group S.A.

Utang-utang marang kapitalisasi buku HLN (Haleon plc)|kenvue.com - Utang-utang marang kapitalisasi buku|Rasio utang marang kapitalisasi buku Verona Pharma (VRNA)|MENS: Rasio utang marang aset resik|LGND (Ligand Pharma) - Rasio utang marang kapitalisasi buku|Amneal Corp (AMRX) - Utang marang nilai buku|PRGO (Perrigo Company plc) - Utang-utang marang kapitalisasi buku|Utang-utang marang kapitalisasi buku alvotech.com (ALVO)|Liquidia (LQDA) - Utang marang nilai buku|Rasio utang marang aset resik GLPG (Galapagos N.V.)|ANIP: Rasio utang marang kapitalisasi buku|MNKD - Utang-utang marang nilai buku|Utang marang nilai buku Amphastar Pharmaceuticals AMPH|PCRX - Utang marang modal buku|Utang-utang marang kapitalisasi buku ARS Pharmaceuticals, Inc. SPRY|Theravance Biopharma Inc (TBPH) - Rasio utang marang aset resik|Utang-utang marang kapitalisasi buku AQST (Aquestive Pharma)|Utang-utang marang nilai buku SCPH|Tectonic Therapeutic, Inc. (TECX) - Rasio utang marang kapitalisasi buku|Rasio utang marang aset resik TNXP (tonixpharma.com)|China SXT Pharmaceuticals, Inc. (SXTC) - Rasio utang marang kapitalisasi buku|Eupraxia Pharmaceuticals, Inc. - Rasio utang-utang marang kapitalisasi buku|Rasio utang marang kapitalisasi buku BioHarvest (BHST)|EXOZ: Rasio utang marang aset resik|Rasio utang marang kapitalisasi buku ORMP|Entera Bio (ENTX) - Utang-utang marang nilai buku|Utang-utang marang kapitalisasi buku HYFT|Utang marang nilai buku ABVC BioPharma Inc.|Utang-utang marang kapitalisasi buku CPIX|Utang-utang marang kapitalisasi buku QNTM (Quantum BioPharma Corp)|FibroGen, Inc. (FGEN) - Rasio utang marang kapitalisasi buku|telomirpharma.com - Rasio utang-utang marang kapitalisasi buku|Rasio utang marang kapitalisasi buku RANI (Rani Therapeutics Inc)|Synergy CHC Corp (SNYR) - Utang-utang marang aset resik|Utang marang nilai buku rallybio.com RLYB|Lexaria Bioscience Corp. (LEXX) - Rasio utang marang aset resik|Pulmatrix, Inc. - Utang-utang marang kapitalisasi buku|Utang marang aset resik PTHL|Aptorum Group Limited (APM) - Rasio utang marang kapitalisasi buku|Rasio utang marang aset resik LYRA (Lyra Therapeutics Inc.)|IBO: Rasio utang marang kapitalisasi buku|TNFA - Utang-utang marang nilai buku|cbdMD Corp - Utang marang nilai buku|PRFX: Utang-utang marang kapitalisasi buku|Rasio utang marang kapitalisasi buku altamiratherapeutics.com (CYTO)|Rasio utang-utang marang kapitalisasi buku Lipella Pharmaceuticals Inc|OPTN - Utang marang nilai buku|Rasio utang marang aset resik PIRS|PTPI (Petros Pharmaceuticals) - Rasio utang marang kapitalisasi buku|Utang-utang marang aset resik qlsyy.net QLI|Utang marang nilai buku SLRN|Utang-utang marang aset resik TFF Pharmaceuticals Inc. TFFP